Duchenne Cell Therapy Decision Slips to November After FDA Labels New Arm Function Data a Major Amendment

FDA pushed the deramiocel decision to November 22 after classifying Capricor’s new 24-month HOPE-3 data as a major amendment to the filing.

Have A Referral?